Transcripts
DR. LINGWOOD:
Another risk factor, is the
transcytosis of the toxin across the epithelial
cell layer in the gastrointestinal tract. This
figure is showing VT1 transcytosis and on the
right is VT2. And this is a model system where
you have monolayer cells and you look for
transit of the toxin from one side to the other.
This is work by Acheson in Boston. And so this
is looking at percentage transit of VT1 when you
add colchesine, which is an inhibitor of
microtubular function. You see that you lose
the ability to translocate the toxin from one
side to the other. Whereas VT2 translocation is
actually stimulated. So that means that the
mechanism by which the toxin leaves the GI
tract and gets into the blood system is
different for the VT1 and VT2.
